Mainland China and Hong Kong should ease listing rules for biotechnology companies and lower takeover thresholds for listed firms to capitalise on renewed foreign interest in the healthcare sector, venture capitalist Nisa Leung said.
“Besides artificial intelligence, Premier Li Qiang also highlighted biomedicine in the ‘two sessions’ annual government work report,” said Leung, a former managing partner at Qiming Venture Partners, speaking in a sideline interview during China’s annual meetings of…
China and Hong Kong should relax biotech listing rules, venture capitalist says
